Despite bureaucratic headaches, the final results to 30 April report a 5% increase in revenue to £3.5m and a reduced loss to £94.8k. The P&L comparison with 2024 is awkward due to changes in accounting practises and the £4.7m impairment charge. The FY 2025 loss was affected by a sharp decline in allowable R&D which was down to £80k from £212k due to HMRC’s new restrictions on overseas development. DXS continues to significantly invest in innovation and developing solutions. These costs are now ....
